<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 13, 2000
MAXIM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
1-14430 87-0279983
(Commission File No.) (IRS Employer Identification No.)
8899 UNIVERSITY LANE, SUITE 400
SAN DIEGO, CALIFORNIA 92122
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (858) 453-4040
<PAGE>
ITEM 5. OTHER EVENTS.
On December 13, 2000 the Company announced that the Oncologic Drugs
Advisory Committee to the U.S. Food and Drug Administration had declined to
recommend approval of the Company's lead drug candidate Maxamine-Registered
Trademark- (histamine dihydrochloride) as an adjuvant to interleukin-2 for
the treatment of patients with advanced metatastic melanoma that have liver
metastases.
A copy of the Press Release is attached hereto as Exhibit 99.1 and
incorporated herein by this reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
EXHIBITS.
99.1 Press Release issued December 13, 2000.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MAXIM PHARMACEUTICALS, INC.
Dated: December 15, 2000 By: /s/ Dale Sander
-------------------------------------
Dale Sander
Chief Financial Officer
(Principal Accounting Officer and
Officer duly authorized to sign this
report on behalf of the Registrant)
<PAGE>
INDEX TO EXHIBITS
99.1 Press Release issued December 13, 2000.
